The Classic Egg-Yolk Macular Dystrophy of Childhood
Bread dough left to rise doesn't stay smooth for long — as it proofs, the surface stretches, sometimes cracks, and eventually settles into whatever shape it will hold once baked. Best disease follows a comparable staged arc beneath the macula: a rounded, golden-yellow deposit begins as a smooth, intact shape, gradually breaks apart over years, and eventually settles into its final form. The name vitelliform, taken from the Latin for egg yolk, simply describes what that early deposit looks like, and it's this staged unfolding, more than any single symptom, that shapes how the condition is followed over time.
One detail regularly surprises Ugandan families at a first consultation: a child can carry a lesion that looks dramatic under examination and still read perfectly comfortably for their age. Lesion appearance and actual visual performance simply aren't tightly linked, which is precisely why getting the staging right matters far more than how striking a retinal photograph happens to look.
As long as the deposit stays whole and unbroken, vision usually holds up remarkably well, sometimes remaining completely normal despite an obvious finding sitting right there under examination. Trouble tends to arrive once that neat shape starts to fragment — a phase people often compare to a scrambled egg — and this is generally when reading small text becomes a strain and central vision starts to blur or warp. Later on, once things reach a more settled stage, the vision loss tends to hold steady rather than fluctuate, though a minority of patients experience a sudden further dip if abnormal new blood vessels start growing beneath the retina.
A defect in the BEST1 gene sits at the root of the condition — this gene is meant to produce bestrophin-1, a protein that governs how ions and fluid pass across the retinal pigment epithelium. Once that process breaks down, fluid and pigment start pooling in the wrong spot beneath the macula, slowly building into the lesion seen on a scan. Passed on as a dominant trait, its effects are anything but consistent — one carrier might show an obvious lesion yet feel nothing at all, while a close relative with the exact same mutation ends up with real, noticeable vision problems.
Testing an eye's electro-oculogram is usually what settles the question, since it reliably comes back abnormal — a distinctly low Arden ratio — even when a plain ERG on that same eye looks perfectly ordinary. It's precisely that contradiction between the two results that steers a specialist toward Best disease rather than something that only looks similar. Repeated OCT scans over time trace exactly how far along the lesion has progressed, and a positive genetic result for BEST1 both locks in the diagnosis and flags relatives worth screening for the same gene.
Because this lesion is entirely capable of remaining unchanged for years on end, doctors tend to favour careful, ongoing observation over any rush toward active treatment, all while staying alert to the modest possibility of abnormal vessel growth as things slowly develop. Only once vision has genuinely started slipping does regenerative stem cell therapy enter serious discussion, aimed at safeguarding whatever central vision is still doing its job.
It's entirely possible, and actually a familiar pattern in early-stage Best disease. The size of a lesion on imaging tells us surprisingly little about how well someone can actually see, which is why staging the disease properly is far more useful than reacting to a dramatic-looking scan.
None at all — this stays entirely confined to the retina and has no connection whatsoever to cancer. It does, however, pass through a recognised sequence of stages as time goes on, and tracking that sequence is exactly what our monitoring is set up to do.
That's a textbook case of variable expressivity, something BEST1 mutations are particularly known for producing. She may well be carrying the identical faulty gene without any lesion or symptom ever developing — testing is really the only way to confirm this one way or the other, rather than assuming she was simply spared.
Far from inevitable — many patients keep solid central vision for decades, especially if their particular lesion never moves beyond its earliest stages. Given how differently this can play out from person to person, regular monitoring is what allows us to react quickly the moment anything actually changes.